Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension.
Sung-A ChangSang Hyun LeeJung Hyun ChoiWook-Jin ChungJae Young ChoiHyung-Kwan KimHae-Ok JungSeong-Mi ParkWon-Jang KimSu Young JungSeo Young SongPublished in: Expert opinion on drug safety (2022)
Our finding that AE incidence did not increase with increasing dose of selexipag would provide supportive real-worldevidence on the management of optimal dose and safety.